Rocuronium Consumption in Etomidate-based and Propofol-based General Anesthesia Under Sevoflurane

NCT ID: NCT02711917

Last Updated: 2016-03-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

175 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-31

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Different concentration of sevoflurane was given to maintain anesthesia. The dose of propofol to maintain BIS between 40-60 and the consumption of rocuronium was recorded and evaluated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

2 age group of patients was selected, 40-60 years and above 60 years. Maintenance of anesthesia was carried out using different concentration of Sevoflurane, ie MAC 0.5, 0.75 and 1.0. Bis value was kept between 40-60 and the dose of propofol required was recorded. Rocuronium infusion given in a close loop infusion system for different group was tabulated. The results was then analysed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuromuscular Monitoring

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SP1- sevoflurane MAC 0.5

In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.5. Propofol infusion is started to keep BIS between 40-60.

Group Type EXPERIMENTAL

MAC 0.5

Intervention Type DRUG

0.5 MAC Sevoflurane

Propofol

Intervention Type DRUG

Propofol consumption

Rocuronium

Intervention Type DRUG

Consumption of Rocuronium

SP2- Sevoflurane MAC 0.75

In this group, patient of age 40-60 years, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen.Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.75. Propofol infusion is started to keep BIS between 40-60.

Group Type EXPERIMENTAL

MAC 0.75

Intervention Type DRUG

0.75 MAC Sevoflurane

Propofol

Intervention Type DRUG

Propofol consumption

Rocuronium

Intervention Type DRUG

Consumption of Rocuronium

SP3 -Sevoflurane MAC 1.0

In this group, patient of age 40-60 years, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 1.0. Propofol infusion is started to keep BIS between 40-60.

Group Type EXPERIMENTAL

MAC 1.0

Intervention Type DRUG

1.0 MAC Sevoflurane

Propofol

Intervention Type DRUG

Propofol consumption

Rocuronium

Intervention Type DRUG

Consumption of Rocuronium

SP4- Sevoflurane MAC 0.5

In this group, patient above 60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Propofol infusion is started to keep BIS between 40-60.

Group Type EXPERIMENTAL

MAC 0.5

Intervention Type DRUG

0.5 MAC Sevoflurane

Propofol

Intervention Type DRUG

Propofol consumption

Rocuronium

Intervention Type DRUG

Consumption of Rocuronium

SP5- Sevoflurane MAC 0.75

In this group, patient above 60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.75. Propofol infusion is started to keep BIS between 40-60.

Group Type EXPERIMENTAL

MAC 0.75

Intervention Type DRUG

0.75 MAC Sevoflurane

Propofol

Intervention Type DRUG

Propofol consumption

Rocuronium

Intervention Type DRUG

Consumption of Rocuronium

SE1- Sevoflurane MAC 0.5

In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.

Group Type EXPERIMENTAL

MAC 0.5

Intervention Type DRUG

0.5 MAC Sevoflurane

Etomidate

Intervention Type DRUG

Etomidate consumption

Rocuronium

Intervention Type DRUG

Consumption of Rocuronium

SE2- Sevoflurane 0.75

In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.

Group Type EXPERIMENTAL

MAC 0.75

Intervention Type DRUG

0.75 MAC Sevoflurane

Etomidate

Intervention Type DRUG

Etomidate consumption

Rocuronium

Intervention Type DRUG

Consumption of Rocuronium

SE3- Sevoflurane MAC 1.0

In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.

Group Type EXPERIMENTAL

MAC 1.0

Intervention Type DRUG

1.0 MAC Sevoflurane

Etomidate

Intervention Type DRUG

Etomidate consumption

Rocuronium

Intervention Type DRUG

Consumption of Rocuronium

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MAC 0.5

0.5 MAC Sevoflurane

Intervention Type DRUG

MAC 0.75

0.75 MAC Sevoflurane

Intervention Type DRUG

MAC 1.0

1.0 MAC Sevoflurane

Intervention Type DRUG

Propofol

Propofol consumption

Intervention Type DRUG

Etomidate

Etomidate consumption

Intervention Type DRUG

Rocuronium

Consumption of Rocuronium

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI \< 30
* elective Gynaecological/abdominal/urological surgery
* Operation time \< 3hrs
* ASA I/II
* Intubated patients

Exclusion Criteria

* Coronary artery disease, cardiac, lung, hepatic and renal insufficiency
* Severe uncontrolled HBP
* Obesity (BMI \>30)
* Neuromuscular and metabolic diseases
* Receiving medication known to influence neuromuscular transmission
* Pregnancy
* Psychiatric disorders
* Allergy history to any of the drugs that will be used
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tianjin Medical University General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Guolin Wang

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Guolin Wang, Professor

Role: PRINCIPAL_INVESTIGATOR

Head of department anesthesiology

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Narina Goulvaden

Identifier Type: OTHER

Identifier Source: secondary_id

TianjinMUGH

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.